COVID-19中类固醇相关高血糖的诊断与管理考量:印度内分泌学会立场声明
印度内分泌学会针对COVID-19大流行中糖皮质激素广泛使用(包括轻症患者和自行用药)导致高血糖、糖尿病酮症酸中毒和毛霉病发病率增加的问题,制定了关于糖皮质激素所致高血糖诊断与管理的立场声明。声明指出糖皮质激素可降低住院重症至危重症患者死亡率,但短期生存获益担忧压过了对长期不良后果的关注,加之药物易得、廉价和短期临床改善明显,导致不加区分地使用。该声明旨在传播类固醇使用期间高血糖优化管理的信息,供临床医生在COVID-19患者中使用糖皮质激素时参考。
要点
- 糖皮质激素可降低住院重症至危重症COVID-19患者死亡率,但临床实践中使用频率空前增加。
- 糖皮质激素使用导致COVID-19患者高血糖发病率增加,并引发糖尿病酮症酸中毒和毛霉病等急性并发症。
- 糖皮质激素因易得、廉价和短期临床改善明显,被不加区分地用于轻症COVID-19患者,包括自行用药。
- 印度内分泌学会制定本立场声明,针对COVID-19患者中糖皮质激素所致高血糖的诊断与管理提供指导。
- 亟需传播类固醇使用期间高血糖优化管理的信息。
适用人群与场景
- COVID-19感染患者,包括住院重症至危重症患者及轻症患者。
红旗征与不能漏的情况
- 使用糖皮质激素的COVID-19患者出现高血糖,可能导致糖尿病酮症酸中毒。
- 使用糖皮质激素的COVID-19患者出现高血糖,可能导致毛霉病。
研究设计与关键结果
- 制定机构:印度内分泌学会(Endocrine Society of India)。
- 方法:制定立场声明,关于COVID-19患者中糖皮质激素所致高血糖的诊断与管理。
- 背景:糖皮质激素可降低住院重症至危重症患者死亡率;但存在不加区分的使用,包括轻症患者和自行用药;使用导致高血糖及糖尿病酮症酸中毒和毛霉病等急性并发症发病率增加。
证据类型、等级与局限
- 证据类型:立场声明(专家共识)。
- 局限:原文未报告局限性
对床旁实践的改变
- 临床医生在COVID-19患者中使用糖皮质激素时,需关注高血糖的发生及糖尿病酮症酸中毒和毛霉病等急性并发症。
- 印度内分泌学会认为亟需传播类固醇使用期间高血糖优化管理的信息。
指南或共识出处
- 印度内分泌学会(Endocrine Society of India)立场声明,发表于Indian J Endocrinol Metab。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
The current coronavirus disease (COVID-19) pandemic is showing no signs of abatement and result in significant morbidity and mortality in the infected patients. Many therapeutic agents ranging widely between antivirals and anti-inflammatory drugs have been used to mitigate the disease burden. In the deluge of the drugs being used for COVID-19 infection, glucocorticoids (GCs) stand out by reducing mortality amongst in-hospital severe-to-critically ill patients. Health-care practitioners have seen this as a glimmer of hope and started using these drugs more frequently than ever in clinical practice. The fear of mortality in the short term has overridden the concern of adverse long-term consequences with steroid use. The ease of availability, low cost, and apparent clinical improvement in the short term have led to the unscrupulous use of the steroids even in mild COVID-19 patients including self-medication with steroids. The use of GCs has led to the increasing incidence of hyperglycemia and consequent acute complications of diabetic ketoacidosis and mucormycosis in COVID-19 patients. There is an urgent need to dissipate information about optimum management of hyperglycemia during steroid use. In view of this, the Endocrine Society of India has formulated this position statement about the diagnosis and management of hyperglycemia due to the use of GCs in patients with COVID-19 infection.
参考来源
- Das S, Rastogi A, Harikumar KVS, et al. Diagnosis and Management Considerations in Steroid-Related Hyperglycemia in COVID-19: A Position Statement from the Endocrine Society of India. Indian J Endocrinol Metab. 2021. PMID: 34386386. doi:10.4103/ijem.ijem_227_21
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。